July 18th 2025
The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.
GU Tumor Board: Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
September 27, 2025
Register Now!
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
FDA approves PET imaging product Gozellix for prostate cancer
March 20th 2025Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
January 24th 202564Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.
Conventional imaging may understage prostate cancer, new data suggest
January 3rd 2025“However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases," says Adrien Holzgreve, MD, MHA.